Will Teclistamab-cqyv be included in medical insurance in 2025?

Teritusumab (Teclistamab-cqyv) is an innovative anti-tumor drug that has attracted much attention in recent years. It was developed by Johnson & Johnson (Janssen) and is the world's first bispecific antibody drug approved for the treatment of relapsed or refractory multiple myeloma. Since its approval in the United States in 2022, teritusumab has been quickly included in international treatment guidelines for multiple myeloma and has been successively launched in Europe, Japan, Canada and other countries. Due to the innovative nature and remarkable efficacy of this drug, it has attracted great attention from clinical experts around the world. However, as of 2025, teritusumab has not yet been officially included in China’s national medical insurance directory.

Judging from the process of drugs entering medical insurance, medical insurance negotiations often need to go through multiple stages, including drug registration approval, clinical data evaluation, economic evaluation, and enterprise quotation negotiation. Teritusumab is currently in the domestic drug registration application stage, and the original drug has not yet been officially approved for marketing in mainland China. Despite this, the industry generally believes that with China's rapid introduction of innovative antibody drugs and the continuous strengthening of national medical insurance's support for innovative drugs, teritusumab has a higher chance of being included in the medical insurance catalog in the future.

It is worth noting that teritusumab is priced higher overseas. In the U.S. market, the monthly treatment cost can be as high as tens of thousands of dollars, mainly due to its complex production process and innovative mechanism. If the drug is listed in China in the future, pharmaceutical companies will usually make the drug price more accessible through medical insurance negotiations, price reductions and profit concessions. In recent years, a number of international innovative antibody drugs (such as daratumumab and isatuzumab) have achieved significant price reductions after negotiation after entering China. Therefore, the industry expects that if teritusumab successfully enters medical insurance, its price is expected to achieve a balanced adjustment to "international standards".

Reference materials:https://www.tecvayli.com/